Prostate cancer presentation and management in the Middle East

Abstract

Background Although prostate cancer is a prevalent malignancy worldwide, its clinical presentation and management in the Middle East are not well-documented. This study aims to provide insights into the initial clinical presentation and management of prostate cancer in this region. Methods A retrospective review was conducted on seven institutional databases from six Middle Eastern countries, including Türkiye, Lebanon, Iraq, Syria, Bahrain, and Jordan, to identify patients diagnosed with prostate cancer in 2021. Descriptive analysis was performed on the collected data to provide an overview of the demographic, clinical, and treatment variables. Results A total of 1,136 patients were identified with a median age of 70 (range, 50–84). Most patients (78%) received their prostate cancer diagnosis after presenting with symptoms, as opposed to routine PSA screening. At the time of diagnosis, 35% of men had clinical T3 or T4 disease, 54% with Stage IV disease and 50% with Gleason score ≥ 8. Regarding treatment, 20% of non-metastatic and 22% of metastatic patients received no treatment. Conclusion Most men in this study sought prostate cancer evaluation due to symptoms and were subsequently diagnosed with advanced-stage disease, providing a foundation for future research aimed at understanding the underlying factors behind the observed trends and enabling informed interventions.

From Despair to Hope: First Arabic Experience of 177Lu-PSMA and 161Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer

“…This fact stems from a significant number of patients being diagnosed at advanced stages, coupled with underdiagnosis of early-stage disease due to inadequate screening rates and limited public awareness, rather than an accurate reflection of the disease’s prevalence. [ 2 , 3 , 4 ]. Ethnic variation and tumor aggressiveness have also been proposed as factors contributing to this divergent incidence pattern [ 2 , 3 , 4 , 5 ].…”

“…[ 2 , 3 , 4 ]. Ethnic variation and tumor aggressiveness have also been proposed as factors contributing to this divergent incidence pattern [ 2 , 3 , 4 , 5 ]. Recent studies have shown a continued rise in new PC cases in Jordan [ 6 ], where it is currently the fifth most common cancer among males nationally and the second most common globally [ 6 , 7 ].…”

Bio-beneficial spectrum of Tecoma stans flower extract in vitro for fighting prostate and ovarian cancers with its anti-diabetic and antioxidant activities

“…Cancer of the prostate is one of the most common kinds of cancer affecting men. Despite the worldwide prevalence of prostate cancer, there is still an important knowledge gap concerning its management and manifestation (Sayan et al 2024). In many nations, prostate cancer is a significant public health issue.…”